Gene Therapy Production Articles & Analysis
27 news found
The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. ...
PT, in Carlsbad, CA Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Chief Medical Officer Maria Escolar, M.D, MS., will present updated clinical data from the RESKUE Phase 1/2 clinical trial for FBX-101—the Company’s novel gene therapy for the ...
Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced further collaboration for their manufacturing partnership to include clinical stage plasmid ...
This will allow our teams to work efficiently together during the development phase and through the manufacturing process.” Cell Therapies CEO, Mr Peter Giannopoulos, said: “As the first Australian site to obtain TGA approval to commence onshore manufacture of CAR-T cell therapy products, we are delighted to now be working with an ...
About RP-L201 RP-L201 is an investigational gene therapy product being developed for severe Leukocyte Adhesion Deficiency-I (LAD-I). The therapy consists of hematopoietic stem cells from the patient that have been genetically modified with a lentiviral vector to contain a functional copy of the ITGB2 gene. ...
(Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the opening of its new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and ...
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development services. The product manager of the company is excited to launch the Gene Therapy Products Characterization service to help clients overcome the challenges of gene ...
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, development and commercial milestone payments, plus royalties ...
Within the facility, the space dedicated for cell and gene therapy will offer integrated CDMO services for mRNA, viral vectors, and plasmid DNA, providing GMP production with multiple segregated cleanrooms to deliver greater manufacturing efficiency. ...
-GI Innovation·GI Cell, respectively establishing a cell therapy center at Severance Hospital·Songdo Severance Hospital(tentative named) -Establishment of the seamless process for research, production, clinical trials, Regulatory affair (RA), and etc. of advanced biopharmaceutical GI Innovation, a new innovative drug development company, announced ...
(Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These latest data show that, as of the November 9, 2021 cutoff date, the investigational ...
Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene ...
(Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. As of the September 17, 2021 cutoff date, results from the four patients treated in the first two ...
At CPhI Worldwide 2021, Thermo Fisher Scientific will showcase its newest capabilities across its global pharma services network which help pharmaceutical and emerging biotech companies accelerate time to market in a wide range of modalities and platforms including cell and gene therapies, drug products and biologics. CPhI 2021 begins with a ...
Unique to Aura GT is the fact that it can also identify DNA leakage in gene therapy products so the mechanism of aggregation can be determined and corrected. “Aura GT is going to completely revolutionize gene therapy product development. Gene therapy ...
This week, Thermo Fisher Scientific will highlight its investments and innovations over the past 12 months across its global pharma services network, which have been focused on areas of accelerated demand including cell and gene therapy, drug product development, biologics manufacturing and clinical supply chain services. ...
Under the terms of the agreement, Senti Bio will be responsible for designing, building and testing cell state- and disease- specific Smart Sensors and Regulator Dials for use in BlueRock Therapeutics’ regenerative medicine product candidates. BlueRock Therapeutics will receive the option to license gene circuits emerging from the collaboration for cell ...
(Nasdaq: BIIB, Cambridge, Mass., USA) to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections. ...
(Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced the signing of a lease agreement for its GMP production facility located in College Station, TX. Construction of the 25,000 ft2 facility will commence in Q4 ...
T-knife is backed by top tier investors Versant Ventures, RA Capital, Andera Partners, and Boehringer Ingelheim Venture Fund. About Catalent Cell & Gene Therapy With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a ...